Nucleic acid and gene derived from novel hcv strain and replicon-replicating cell using said gene
CA 2539457 C · Owner: Tokyo Metropolitan Organization For Medical Research · Inventors: Kato, Takanobu; Wakita, Takaji; Miyamoto, Michiko
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to a gene derived from a novel fulminant hepatitis C virus , strain, an HCV replicon RNA with a high replication efficiency obtained using the gene, and , an HCV replicon-replicating cell transfected with the replicon RNA. When the HCV , replicon RNA and the HCV replicon-replicating cell of the present invention are used, HCV , proteins can be continuously produced in a large amount.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 16, 2004 and granted December 3, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended September 16, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 16, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.